Tagged with Bayer

UAE Bassam Abdallah, Country Division Head of Bayer Healthcare, speaks about the UAE’s economic diversification evolution, how healthcare is the leading segment in this process, and what Bayer’s strategy is to keep up with the regions changing disease portfolio. In many ways the UAE is becoming a model for other countries…

Bayer Austria GmbH You have been with Bayer for almost 15 years. What would you say defines your loyalty to the company, and has the time so far met your original expectations? Bayer is a great company today; it was also a great company when I joined in 1998. The fascination with innovation…

Bayer Ireland Mr. Zimmermann, you came to manage the Irish affiliate of Bayer in 2010, after heading Business Management for Bayer Pharma Headquarters in Berlin. After these two years, what are your impressions of the state and nuances of the Irish market, and what would you say surprised you most about the…

Bayer Healthcare South Africa Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes in the company’s development, and to what extent does Bayer’s recent development reflect the market changes? The first change has…

Bayer Schering Pharma The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global market. Given that the company seems to be finished with mergers and acquisitions for the time being, what are Bayer…

Array Liam Condon, Managing Director of Bayer Healthcare China discusses the  government’s recent announcements regarding its much-anticipated healthcare reform plan, the future benefits of investing in rural healthcare, and the company’s main ambitions in China over the next five years.         It has been a rollercoaster four years…

Bayer Australia Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines in the industry. In Australia, the company is launching in the next three years, 18 new products or product line…

Bayer Thailand Mr. Ammelburg of Roche described Thailand as a very difficult and different market and according to PReMA figures there was only 2 percent growth last year. Nevertheless, global projections rank Thailand as 12th among emerging countries in pharma and anticipate Thailand becoming the eighth largest economy and market by 2016.…

Bayer Schering Pharma Argentina The Bayer Schering merger in 2006 saw you add Argentina and Bolivia to your existing responsibilities as General Manager of Schering for Paraguay and Uruguay. What have been some of the challenges you have faced since that time? Argentina is a challenging market, and the system is very complex. This…

Bayer UK/Ireland Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave mature markets, such as the UK and how do you aim to position the company locally? The UK is perceived…

Bayer Healthcare Pharmaceuticals Russia You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed, and what do you find most striking? The biggest difference is the fact that the government is much more involved…

Bayer Co. Malaysia / Bayer Healthcare Malaysi Can you give our readers an outline of Bayer’s background in Malaysia and its current organisational division? Herbert Dittmar (HD): Bayer has been in Malaysia for around fifty years. It established its first legal entity here in the early 1970s and then engaged in a number of acquisitions worldwide including…